9月5日，日联科技涨5.07%，截至发稿，报59.68元/股，成交1.61亿元，换手率2.56%，总市值98.83亿 元。 金鹰元和混合A（002681）成立日期2016年5月25日，最新规模5149.35万。今年以来收益15.85%，同类 排名3887/8178；近一年收益33.98%，同类排名3741/7978；成立以来收益115.04%。 金鹰元和混合A（002681）基金经理为倪超。 截至发稿，倪超累计任职时间10年90天，现任基金资产总规模30.16亿元，任职期间最佳基金回报 156.51%， 任职期间最差基金回报-21.21%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，日联科技集团股份有限公司位于江苏省无锡市新吴区漓江路11号，成立日期2009年7月22 日，上市日期2023年3月31日，公司主营业务涉及公司是国内领先的工业X射线智能检测装备供应商,主 要从事微焦点和大功率X射线智能检测装备的研发、生产、销售与服务,产品和 ...

Core Insights - The demand for high-precision inspection in China is significantly increasing due to advancements in industrial manufacturing, particularly in semiconductor, electronic manufacturing, and new energy battery sectors [1][5] - The market size for China's industrial micro-focus X-ray source industry is projected to reach 1.58 billion yuan in 2024, representing a year-on-year growth of 29.51% [1][5] - The global market size for industrial micro-focus X-ray sources is expected to reach 736 million USD in 2024, with a year-on-year growth of 21.71% [5] Industry Overview - Industrial micro-focus X-ray sources are high-precision X-ray emission devices characterized by extremely small focal sizes (typically at the micron level), capable of producing high-energy, high-resolution X-ray beams for precise internal structure inspection [2][3] - The industry is categorized into open tube and closed tube micro-focus X-ray sources based on sealing technology [2] Industry Value Chain - The upstream of the industrial micro-focus X-ray source industry includes raw materials and components such as vacuum glass, ceramic electrodes, reflective target materials, and X-ray tubes [2] - The midstream involves the production and manufacturing of industrial micro-focus X-ray source equipment [2] - The downstream applications include integrated circuits, electronic manufacturing, new energy batteries, and industrial inspection [2] Market Size - The industrial micro-focus X-ray source market is expanding due to the increasing demand for high-precision inspection in semiconductor and electronic manufacturing [5] - The market size for the non-destructive testing industry in China is projected to reach 19 billion yuan in 2024, with a year-on-year growth of 2.15% [3] Key Companies - Dayun Technology (日联科技) has made significant advancements in the field of industrial micro-focus X-ray sources, achieving breakthroughs in technology and product quality, and has established a vertical integration model covering the entire spectrum of X-ray sources [6][7] - Dayun Technology reported a revenue of 200 million yuan in Q1 2025, reflecting a year-on-year growth of 33.19% [7] - Dandong Aolong Ray Instrument Group focuses on the development and production of industrial X-ray detection equipment and has a strong technical foundation in micro-focus X-ray sources [8] Industry Development Trends 1. The industry is accelerating towards 3D/CT technology to enhance defect identification capabilities, particularly in semiconductor packaging and new energy battery manufacturing [9] 2. There is a shift towards online automation to meet modern manufacturing demands for efficient production and quality control, enabling real-time monitoring and reducing manual intervention [10] 3. The integration of artificial intelligence and big data technologies is driving the industry towards AI intelligence, enhancing detection efficiency and accuracy through automated defect recognition [10]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Core Viewpoint - Dayun Technology's half-year performance report for 2025 shows significant revenue growth driven by strong demand and AI integration in industrial X-ray detection equipment [2][3][4]. Financial Performance - In the first half of 2025, Dayun Technology achieved revenue of 460 million yuan, a year-on-year increase of 38.34% [2][3]. - The net profit attributable to shareholders was 83 million yuan, up 7.8% year-on-year, while the net profit excluding non-recurring items was 60 million yuan, reflecting a 15.34% increase [3]. - The gross profit margin was 44.11%, a decrease of 1.31 percentage points compared to the previous year [3]. Business Segments - Revenue from X-ray intelligent detection equipment reached 409 million yuan, growing 40.67% year-on-year, with a gross margin of 44.83%, an increase of 1.22 percentage points [3]. - Specific revenue growth in key sectors includes: - Integrated circuit and electronics manufacturing: 211 million yuan, up 54.63%, gross margin of 50.42% [3]. - New energy battery testing: 98 million yuan, up 69.17%, gross margin of 32.27% [3]. - Castings and welding materials testing: 92 million yuan, up 1.21% [3]. - Spare parts and other revenue amounted to 51 million yuan, a 23% increase [3]. Market Dynamics - The company is leveraging AI technology to enhance detection accuracy, expand application scenarios, and reduce production costs in the industrial X-ray detection equipment sector [4]. - Dayun Technology has established an AI research institute and an AI development center to continuously upgrade its AI models for industrial X-ray imaging [4]. Strategic Moves - The company made significant strides in mergers and acquisitions, investing in Innovative Electronics and Zhuhai Jiuyuan, which align with its business strategy and are expected to create new growth opportunities [5]. - The acquisitions are expected to enhance synergy in technology, products, and market reach [5]. Future Outlook - The company is positioned to benefit from structural growth opportunities in the industrial X-ray detection industry, driven by domestic substitution trends and increasing demand in the semiconductor and lithium battery sectors [5]. - Earnings per share (EPS) forecasts for 2025, 2026, and 2027 are projected at 1.13 yuan, 1.54 yuan, and 2.16 yuan, respectively [5].

9月2日，日联科技跌5.15%，截至发稿，报58.62元/股，成交2.03亿元，换手率3.15%，总市值97.07亿 元。 金鹰元和混合A（002681）成立日期2016年5月25日，最新规模5149.35万。今年以来收益22.01%，同类 排名3779/8184；近一年收益36.93%，同类排名3871/7971；成立以来收益126.46%。 金鹰元和混合A（002681）基金经理为倪超。 截至发稿，倪超累计任职时间10年87天，现任基金资产总规模30.16亿元，任职期间最佳基金回报 156.51%， 任职期间最差基金回报-16.15%。 资料显示，日联科技集团股份有限公司位于江苏省无锡市新吴区漓江路11号，成立日期2009年7月22 日，上市日期2023年3月31日，公司主营业务涉及公司是国内领先的工业X射线智能检测装备供应商,主 要从事微焦点和大功率X射线智能检测装备的研发、生产、销售与服务,产品和技术应用于集成电路及电 子制造、新能源电池、铸件焊件及材料等检测领域。 从基金十大重仓股角度 数据显示，金鹰基金旗下1只基金重仓日联科技。金鹰元和混合A（002681）二季度持有股数3.33万股， 占基金净值 ...

证券日报网讯9月1日晚间，日联科技发布公告称，2025年8月份，公司未实施股份回购。截至2025年8月 31日，公司已累计回购股份108，455股，占公司总股本的比例为0.0655%。 ...

证券代码：688531 证券简称：日联科技 公告编号：2025-059 日联科技集团股份有限公司 因公司实施 2024 年度权益分派事项，本次以集中竞价交易方式回购股份价格 上限由不超过人民币 101.87 元/股（含）调整为不超过人民币 70.03 元/股（含）。 具体内容详见公司于 2025 年 7 月 10 日在上海证券交易所网站（www.sse.com.cn） 披露的《关于 2024 年度权益分派实施后调整回购股份价格上限的公告》（公告编 号：2025-048）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购进展情况公告如下： 2025 年 8 月，公司未实施股份回购。 截至 2025 年 8 月 31 日，公司已累计回购股份 108,455 股，占公司总股本 165,593,939 股的比例为 0.0655%，回购成交的最高价为 46.29 元/股，最低价为 45.94 元/股，支付的资金总额为人民币 500.00 万元（不含 ...

格隆汇9月1日丨日联科技(688531.SH)公布，2025年8月，公司未实施股份回购。截至2025年8月31日， 公司已累计回购股份108,455股，占公司总股本165,593,939股的比例为0.0655%，回购成交的最高价为 46.29元/股，最低价为45.94元/股，支付的资金总额为人民币500.00万元（不含交易费用）。 ...

Core Insights - The company reported a revenue of 460 million in the first half of 2025, representing a year-on-year growth of 38%, while the net profit attributable to shareholders was 83 million, up 8% year-on-year [1] - The growth in net profit was slower than revenue growth due to increased expenses from new overseas factories, AI research center establishment, and employee stock incentive plans [1] Revenue Breakdown - The revenue from X-ray intelligent detection equipment reached 410 million in the first half of 2025, a 41% increase year-on-year, with a gross margin improvement of 1 percentage point to 43% [2] - Revenue from integrated circuits and electronics manufacturing was 210 million, up 55% year-on-year, accounting for 46% of total revenue with a gross margin of 50% [2] - Revenue from the new energy battery detection sector was 98 million, a 69% increase year-on-year, representing 21% of total revenue with a gross margin of 32% [2] - Domestic revenue was 410 million, a 35% increase year-on-year, while export revenue was 50 million, up 83% [3] Technological Advancements and Market Position - The company secured 44 new intellectual property registrations or authorizations, including 11 invention patents, totaling 650 intellectual property rights as of June 30, 2025 [4] - New orders nearly doubled year-on-year in the first half of 2025, with contract liabilities of 75 million, a 28% increase year-on-year [4] - The company launched 8 new X-ray source products, with some gaining recognition from leading clients in the semiconductor sector [4] Mergers and Acquisitions - The company made strategic investments in Innovative Electronics and Zhuhai Jiuyuan, expanding its product offerings in X-ray detection systems and new energy power conversion [5] - The company is actively pursuing global M&A opportunities to enhance its industrial detection technology portfolio [5] Financial Forecast - Projected revenues for 2025-2027 are 1.05 billion, 1.5 billion, and 1.9 billion, with year-on-year growth rates of 41%, 43%, and 27% respectively [6] - Expected net profits for the same period are 200 million, 320 million, and 450 million, with compound annual growth rates of 46% [6]

据证券之星公开数据整理，近期日联科技（688531）发布2025年中报。截至本报告期末，公司营业总收 入4.6亿元，同比上升38.34%，归母净利润8279.36万元，同比上升7.8%。按单季度数据看，第二季度营 业总收入2.61亿元，同比上升42.55%，第二季度归母净利润4746.52万元，同比上升10.44%。本报告期 日联科技公司应收账款体量较大，当期应收账款占最新年报归母净利润比达228.16%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率44.12%，同比减2.88%，净利率17.9%，同比减 22.42%，销售费用、管理费用、财务费用总计8724.15万元，三费占营收比18.95%，同比增9.56%，每股 净资产29.2元，同比增5.2%，每股经营性现金流0.45元，同比增240.93%，每股收益0.72元，同比增 7.46% 财报体检工具显示： 建议关注公司现金流状况（近3年经营性现金流均值/流动负债仅为11.24%） 建议关注公司应收账款状况（应收账款/利润已达228.16%） 分析师工具显示：证券研究员普遍预期2025年业绩在1.87亿元，每股收益均值在1.57元。 | 项目 | 2 ...